Metformin may decrease of lung cancer among nonsmokers with diabetes
the ONA take:
According to a new study published in the journal Cancer Prevention Research, researchers have found that nonsmokers who took metformin to treat their type 2 diabetes had a decreased risk for developing lung cancer compared with those who did not take antidiabetic drug.
For the retrospective cohort study, researchers analyzed data from health-related surveys completed by 47,351 patients with diabetes between 1994 and 1996. By looking at electronic pharmacy records, researchers found that 46% of those had filled at least two prescriptions for metformin within a 6-month period, defined as ever-users.
Results showed that during the 15-year follow-up, 747 patients developed lung cancer, 80 of whom were nonsmokers while 203 were current smokers. Researchers found no association between metformin use and a decreased overall lung cancer risk, but they observed a 43% risk reduction among patients with diabetes who had never smoked.
Although not statistically significant, researchers found that nonsmokers who took metformin for at least 5 years had a 52% decreased risk for developing lung cancer.
The findings suggest that metformin may decrease the risk of lung cancer in nonsmokers, but large, prospective studies are warranted to determine if metformin can decrease the risk of developing certain cancers.
Nonsmokers who took metformin to treat their type 2 diabetes had a decreased risk for developing lung cancer.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|